BIOBADATOP Spanish Atopic Dermatitis Registry: description and early findings

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Munera Campos, Mónica
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.contributor.author Curto Barredo, Laia
• dc.contributor.author Bertolín Colilla, Marta
• dc.contributor.author Carrascosa Carrillo, José Manuel
• dc.date.accessioned 2024-02-19T07:20:59Z
• dc.date.available 2024-02-19T07:20:59Z
• dc.date.issued 2023
• dc.description Article disponible en castellà: http://hdl.handle.net/10230/59125
• dc.description.abstract Background: In recent years, remarkable improvements in our understanding of atopic dermatitis (AD) have revolutionized treatment perspectives, but access to reliable data from clinical practice is essential. Materials and method: The Spanish Atopic Dermatitis Registry, BIOBADATOP, is a prospective, multicenter database that collects information on patients of all ages with AD requiring systemic therapy with conventional or novel drugs. We analyzed the registry to describe patient characteristics, diagnoses, treatments, and adverse events (AEs). Results: We studied data entries for 258 patients who had received 347 systemic treatments for AD. Treatment was discontinued in 29.4% of cases, mostly due to a lack of effectiveness (in 10.7% of cases). A total of 132 AEs were described during follow-up. Eighty-six AEs (65%) were linked to a systemic treatment, most commonly dupilumab (39AEs) and cyclosporine (38AEs). The most common AEs were conjunctivitis (11patients), headache (6), hypertrichosis (5), and nausea (4). There was 1severe AE (acute mastoiditis) associated with cyclosporine. Conclusions: Initial findings on AEs from the Spanish BIOBADATOP registry are limited by short follow-up times precluding comparisons or calculation of crude and adjusted incidence rates. At the time of our analysis, no severe AEs had been reported for novel systemic therapies. BIOBADATOP will help answer questions on the effectiveness and safety of conventional and novel systemic therapies in AD.
• dc.format.mimetype application/pdf
• dc.identifier.citation Munera-Campos M, Chicharro P, Gonzalez Quesada A, Flórez Menéndez Á, de la Cueva Dobao P, Gimenez Arnau AM et al. BIOBADATOP Spanish Atopic Dermatitis Registry: description and early findings. Actas Dermosifiliogr. 2023 Jun;114(6):t479-t87. DOI: 10.1016/j.ad.2023.05.010
• dc.identifier.doi http://dx.doi.org/10.1016/j.ad.2023.05.010
• dc.identifier.issn 0001-7310
• dc.identifier.uri http://hdl.handle.net/10230/59124
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Actas Dermosifiliogr. 2023 Jun;114(6):t479-t87
• dc.rights © 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Treatments
• dc.subject.keyword Atopic dermatitis
• dc.subject.keyword Adverse events
• dc.subject.keyword Biologics
• dc.subject.keyword JAK inhibitors
• dc.subject.keyword Registries
• dc.title BIOBADATOP Spanish Atopic Dermatitis Registry: description and early findings
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion